<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912301</url>
  </required_header>
  <id_info>
    <org_study_id>08-001003</org_study_id>
    <secondary_id>R01DK054681</secondary_id>
    <secondary_id>R01DK079866</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <secondary_id>1RC1DK086182</secondary_id>
    <nct_id>NCT00912301</nct_id>
  </id_info>
  <brief_title>Cheno Effect on Transit in Health and IBS-C</brief_title>
  <acronym>Chenotransit</acronym>
  <official_title>Effect of Chenodeoxycholic Acid on Gastrointestinal Transit and Colonic Functions in Health and Constipation-predominant Irritable Bowel Syndrome (IBS-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid,
      induces acceleration of colonic transit in health and in patients with
      constipation-predominant Irritable Bowel Syndrome (IBS-C).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: A hydrophobic di-alpha hydroxy bile salt, sodium chenodeoxycholate (CDC),
      delivered in a delayed release capsule to the ileocolonic region of the colon induces
      acceleration of colonic transit in patients with constipation-predominant IBS.

      Methods: We shall study 36 patients with IBS-C, aged 18-65 years, and each treatment group
      will be balanced on gender and Body Mass Index (BMI) in the randomization. All patients will
      be assessed for symptoms of functional gastrointestinal disorder or psychological disturbance
      will be characterized in a standard fashion with questionnaires (Talley et al 1989), the
      Psychosomatic Symptom Checklist (SCL-90) and the Hospital Anxiety and Depression Inventory
      [HAD (Zigmond and Snaith 1983)]. With appropriate consent, a venous blood sample will be
      obtained from each participant for DNA extraction. Fasting Serum
      7alpha-hydroxy-4-cholesten-3-one (7alpha-CHO) will be measured in all to ensure they do not
      have evidence of asymptomatic bile acid malabsorption. The normal range in our lab is &lt;61
      ng/mL.

      Experimental design: A randomized, double blind, placebo controlled, dose-response parallel
      group design, with concealed allocation. Participants will undergo an initial baseline
      colonic transit for 24 hours to obtain Colonic Geometric Center (GC24). Sodium
      chenodeoxycholate (CDC) will be delivered to the ileocolonic region to assess ascending colon
      and whole colonic transit in participants with IBS-C; 12 participants per group will be
      randomized to placebo, 0.5 or 1 gram CDC each for a period of 4 days with the transit study
      conducted during the last 48 hours of drug ingestion. The CDC will be placed in gelatin
      capsules that are coated with methacrylate (EUDRAGIT-LÂ®), a pH-sensitive polymer that will
      result in release of the active ingredient in the terminal ileum.

      Experimental procedure: At standardized times (hourly for first 8 hours, and at 12, 24 and 48
      h), dual gamma camera scans will be obtained to measure ascending colon and overall colonic
      transit. Patients will fill daily diaries to evaluate stool, frequency, consistency and ease
      of passage.

      Gastrointestinal and Colonic Transit: A validated scintigraphic method to measure gastric,
      small bowel, and colonic transit will be used. A methacrylate-coated capsule dissolves in the
      alkaline pH of the distal ileum to release 111In-labeled activated charcoal particles to
      evaluate colonic transit on sequential scans. Meanwhile, orally ingested 99 mTc-labeled egg
      meal allows measurement of gastric and small bowel transit. (Technetium [99mTc] sestamibi
      (trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging.) We have
      previously shown that the gastric emptying (GE) at 2 and 4 hours, colonic filling (CF) at 6
      hours, and colonic geometric center (GC, weighted average of isotopic counts) in colon at 4,
      24 and 48 hours provide excellent summaries of gastric emptying and colonic transit with
      similar diagnostic accuracy as more detailed, costly, and time-consuming analyses. The normal
      values for these parameters have been previously published (Cremonini et al).

      Scintigraphic gastric emptying and intestinal/colonic transit analysis: A variable region of
      interest program will be used to measure transit, as in previous studies from our lab.
      Radioisotope content in each region (gastric, ascending, transverse, descending,
      rectosigmoid) will be corrected for decay and tissue attenuation or depth.

      Anticipated Result: CDC will accelerate whole colonic transit and loosen stool form in
      patients with constipation predominant IBS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic Geometric Center at 24 Hours (GC24)</measure>
    <time_frame>after 4 days of treatment</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colonic Transit at 48 Hours (GC48)</measure>
    <time_frame>after 4 days of treatment</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascending Colon Emptying (AC t_1/2)</measure>
    <time_frame>after 4 days' treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>after 4 days' treatment</time_frame>
    <description>The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Filling at 6 Hours</measure>
    <time_frame>after 4 days' treatment</time_frame>
    <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>NaCDC 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCDC 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chenodeoxycholate (NaCDC)</intervention_name>
    <description>500 or 1000 milligrams NaCDC per day each for a period of 4 days</description>
    <arm_group_label>NaCDC 500 mg</arm_group_label>
    <arm_group_label>NaCDC 1000 mg</arm_group_label>
    <other_name>Chenodiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy volunteers:

          -  Age (yr) 18-65

          -  Gender (F:M)3.5 :1

          -  Bowel Disease Questionnaire (BDQ) - IBS symptoms negative by Rome III criteria

          -  Hospital Anxiety/Depression score &lt;8

        IBS patients:

          -  Age (yr) 18-65

          -  Gender (F:M) 5 :1

          -  BDQ - IBS symptoms: positive by Rome III criteria

          -  Hospital Anxiety/Depression score: No restrictions

        Exclusion Criteria:

          -  Abdominal surgery (except appendectomy or cholecystectomy)

          -  GI medications during the 48h prior to transit measurement

          -  Aspartate/Alanine transaminases &gt;2 X Upper Limit of Normal (ULN)

          -  Other Medications except stable doses of estrogen, thyroid, low dose antidepressants
             of the dopaminergic or serotonergic class
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L. Camilleri, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther. 2002 Oct;16(10):1781-90.</citation>
    <PMID>12269971</PMID>
  </reference>
  <results_reference>
    <citation>Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R, Zinsmeister AR. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010 Nov;139(5):1549-58, 1558.e1. doi: 10.1053/j.gastro.2010.07.052. Epub 2010 Aug 4.</citation>
    <PMID>20691689</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <results_first_submitted>May 29, 2012</results_first_submitted>
  <results_first_submitted_qc>May 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2012</results_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <name_title>Michael Camilleri, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>chenodeoxycholate, IBS, transit, colon, constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between April 17 and November 20, 2009 from 150 mile geographical area around Mayo Clinic, Rochester, MN.</recruitment_details>
      <pre_assignment_details>40 patients signed informed consent, but 3 failed screening due to presence of evacuation disorder, and 1 withdrew prior to study due to illness.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NaCDC 500 mg</title>
          <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
        </group>
        <group group_id="P2">
          <title>NaCDC 1000 mg</title>
          <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NaCDC 500 mg</title>
          <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
        </group>
        <group group_id="B2">
          <title>NaCDC 1000 mg</title>
          <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="3.3"/>
                    <measurement group_id="B2" value="46.1" spread="2.6"/>
                    <measurement group_id="B3" value="40.8" spread="2.3"/>
                    <measurement group_id="B4" value="42" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Colonic Geometric Center at 24 Hours (GC24)</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>after 4 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NaCDC 500 mg</title>
            <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>NaCDC 1000 mg</title>
            <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Geometric Center at 24 Hours (GC24)</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.4"/>
                    <measurement group_id="O2" value="3.5" spread="0.4"/>
                    <measurement group_id="O3" value="2.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Transit at 48 Hours (GC48)</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>after 4 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NaCDC 500 mg</title>
            <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>NaCDC 1000 mg</title>
            <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit at 48 Hours (GC48)</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.3"/>
                    <measurement group_id="O2" value="4.3" spread="0.3"/>
                    <measurement group_id="O3" value="3.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ascending Colon Emptying (AC t_1/2)</title>
        <time_frame>after 4 days' treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NaCDC 500 mg</title>
            <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>NaCDC 1000 mg</title>
            <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ascending Colon Emptying (AC t_1/2)</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.9"/>
                    <measurement group_id="O2" value="8.2" spread="1.8"/>
                    <measurement group_id="O3" value="15.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency</title>
        <description>The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.</description>
        <time_frame>after 4 days' treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NaCDC 500 mg</title>
            <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>NaCDC 1000 mg</title>
            <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Consistency</title>
          <description>The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.5"/>
                    <measurement group_id="O2" value="4.4" spread="0.4"/>
                    <measurement group_id="O3" value="2.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Dunnett's test</method>
            <method_desc>pairwise comparison low dose NaCDC against placebo</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Dunnett's test</method>
            <method_desc>pairwise comparison high dose NaCDC against placebo</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Filling at 6 Hours</title>
        <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
        <time_frame>after 4 days' treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NaCDC 500 mg</title>
            <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>NaCDC 1000 mg</title>
            <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Filling at 6 Hours</title>
          <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
          <units>percentage of the radio-labeled meal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="6.7"/>
                    <measurement group_id="O2" value="54.8" spread="7.1"/>
                    <measurement group_id="O3" value="50.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the 4 days of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NaCDC 500 mg</title>
          <description>Participants randomized to this arm received 500 mg NaCDC per day for 4 days.</description>
        </group>
        <group group_id="E2">
          <title>NaCDC 1000 mg</title>
          <description>Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants randomized to this arm received a placebo capsule each day for 4 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower abdominal cramping/pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Light-headedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael L. Camilleri, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-2306</phone>
      <email>camilleri.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

